The Clap Rameda’s profits (RMDA) increased during Q1-2022 to reach EGP 71.77 million, compared to EGP 30 million in the same period in 2021.
The deets The company’s revenues increased by 26.7% to reach EGP 343.1 million in the period from January 2022 to March, compared to EGP 270.8 million during Q1-2022 in 2021.
The company attributed this increase in profits to the growth of the company’s portfolio of antibiotics, especially “Rametax” and “Rameceftrax”, in addition to the profits of “Cologne”, which recorded the highest sales on the company’s list.
In related news
Last month, the Saudi Public Investment (PIF) increased its stake in Rameda to 11.01%.